American Journal of Kidney Diseases
Volume 48, Issue 4 , Pages 537-545, October 2006

The Epidemiology of Hemoglobin Levels in Patients With Type 2 Diabetes

  • Merlin C. Thomas, MBChB, PhD, FRACP

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Merlin C. Thomas, MBChB, PhD, FRACP, Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, PO Box 6492, Melbourne, VIC 8008, Australia.
  • ,
  • Con Tsalamandris, MBBS
  • ,
  • Richard J. MacIsaac, MBBS, BSc, PhD
  • ,
  • George Jerums, MD, FRACP

Danielle Alberti Memorial Centre for Diabetes Complications, Baker Heart Research Institute; and Endocrine Centre and Department of Medicine, Austin Health and the University of Melbourne, Melbourne, Australia.

Received 3 March 2006; accepted 13 June 2006. published online 29 August 2006.

Background: Anemia is a common finding in patients with diabetes, for whom it constitutes an additional burden. The aim of this study is to clarify the natural history of anemia in patients with type 2 diabetes and describe factors that predict a decrease in hemoglobin (Hb) levels. Methods: A 5-year prospective cohort study was designed as a follow-up of 503 individuals with type 2 diabetes in a single diabetes clinic. In addition to standard management, a full blood count was obtained at each routine visit. No intervention was undertaken to modify Hb levels. Results: At baseline, 12% of patients had anemia, and an additional 13% developed anemia during follow-up. Overall Hb levels decreased by −0.07 ± 0.01 g/dL/y, suggesting that anemia is the end point of a process that begins more than 10 years previously with the initiation of vascular damage. The greatest decreases in Hb levels were seen in patients with macroalbuminuria, renal impairment, or established macrovascular disease at baseline (all P < 0.01). In patients with microvascular disease, decreasing Hb levels tracked with decreasing glomerular filtration rates (GFRs). Patients with an estimated GFR greater than 90 mL/min/1.73 m2 (>1.5 mL/s) or normoalbuminuria had stable Hb levels during the 5-year follow-up. In patients with anemia in our cohort who were managed conservatively, Hb levels decreased by 0.09 ± 0.03 g/dL/y. This decrease was associated with HbA1c levels, but not renal function. Conclusion: This study defines the natural history of Hb levels in patients with type 2 diabetes. Early identification of anemia may be achieved by means of annual or biannual screening in high-risk groups with nephropathy, advanced age, or macrovascular disease. These data are important for developing a rational response to the prevention and management of anemia.

Index Words:  Anemia , diabetes , diabetic nephropathy , hemoglobin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2006.06.011 on August 29, 2006.Support: The costs for measurement of iron storage indices were defrayed by a grant from Jansen-Cilag (manufacturer of epoetin). The costs of erythropoietin levels were defrayed by a grant from Amgen (manufacturers of darbepoetin). Neither party had a role in the study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication. M.C.T. and G.J. were both members of the Jannsen-Cilag Endocrinology advisory panel (2001 to 2002). Potential conflicts of interest: None.

PII: S0272-6386(06)01082-1

doi:10.1053/j.ajkd.2006.06.011

American Journal of Kidney Diseases
Volume 48, Issue 4 , Pages 537-545, October 2006